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ABSTRACT 
AIM 
A Prospective, Randomized Double Blind Study to Compare  the 
Effectiveness of Prophylactic  Granisetron versus Pethidine, for the 
Prevention  of  Postoperative Shivering in Patients undergoing Elective 
Thyroid  Surgeries 
Key Words: Shivering ,Granisetron, Pethidine, Post operative. 
METHODS  
This study was approved by institutional Ethical committee of Madras 
Medical College of  Chennai.  The  study  was  A Prospective, 
Randomized Double Blind Study to Compare  the Effectiveness of 
Prophylactic  Granisetron versus Pethidine, for the Prevention  of  Post 
operative Shivering in Patients undergoing Elective Thyroid  Surgeries. 
Informed  consent obtained from patients regarding study.90 patients 
randomly allocated into three groups.group P,group G,and group S 
receives Pethidine, Granisetron and Saline repectively. 
  
RESULTS: 
 No shivering  occurs  in  Pethidine group 83.3%(n=25), Granisetron 
73%(n=22), placebo group27%(n=8) P-value statistically not significant 
between Granisetron and Pethidine groups but significant(P<0.05) in 
placebo group. Shivering  occurs at grade 3 in  Pethidine group 
7%(n=2), Granisetron10%(n=3), placebo group60%(n=18) P-value 
statistically not significant between Granisetron and Pethidine groups 
but significant in placebo group(P<0.05) 
CONCLUSION 
From this study prophylactic use of both  Granisetron and Pethidine 
were equally effective for the prevention of postoperative shivering. 
Granisetron also  prevents postoperative nausea   and vomiting. 
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                                                 INTRODUCTION 
 
 Shivering  after  anaesthesia  is  the most frequent problem during  the 
early recovery phase of  general anaesthesia  and during neuroaxial 
anaesthesia. Incidence   of   postanaesthesia shivering   occurs  following  
general anaesthesia  is  between 40 – 60%. Postoperative shivering  was 
in 6th position of among 33 low morbidity clinical outcomes(3).  The   
incidence    of   shivering   following  general  anaesthesia  or  
neuroaxial  anaesthesia depends upon the gender, age,  room ambient 
temperature, drugs used  and the duration of the procedure. Following 
anaesthesia   shivering is  extremely  discomfort to patients and  can 
increase postoperative pain. Postoperative shivering   also causes several 
physiological changes such as increased  in sympathetic  stimulation,  
increased   tissue  oxygen consumption and carbondioxide  production 
which results in raised minute ventilation which increased stress on the 
cardiopulmonary system. Cardiac   output  and  metabolic  oxygen  
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 demand  is   also increased. Metabolic acidosis, oxygen desaturation, 
and hypoxemia may occur in elderly patients   with   limited   
cardiopulmonary   reserve. There   are number of    several   studies   
have been conducted for the pharmacological prevention and 
management   of postoperative shivering. The   following drugs are used 
to treat shivering which are Pethidine, Tramadol, Clonidine, and 
Ketamine. Among   these drugs Pethidine  found  to be most effective in 
prevention of postoperative shivering although  its action not completely 
understood.   But    it   may act  through    kappa opioid receptors(5)   
directly on the thermoregulatory centre. The study by Alfonsi et(11) al  
Studies suggested the  role of serotonergic system in control of 
postanaesthetic shivering. Serotonin (5-Hydroxytryptamine) is generally 
present in the brain and spinal cord, which is biological amine in nature. 
5-HT3 receptor antagonist is effective in the prevention   of emetic   
symptoms. Granisetron is a 5-HT3 receptor antagonist. Asif Iqbal(1) and 
his colleagues conducted a study comparing the prophylactic use  of 
Granisetron 40 microgram/Kg body weight and Pethidine for prevention  
                                                       
 3 
 
of  postoperative shivering in patients undergoing general anaesthesia. 
 We designed a study   in our hospital for the prevention of 
postanaesthesia shivering following general anaesthesia by Prophylactic 
use of intravenous injection Granisetron and Prophylactic use of 
intravenous injection   Pethidine  and compare the effectiveness of these 
two  drugs for the prevention of postoperative shivering.                    
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                             AIM OF THE STUDY 
 
 
To   Compare  the  Effectiveness    of   Prophylactic   Granisetron  
versus  Pethidine, for  the   Prevention    of   Postoperative  Shivering  in  
patients   undergoing   Elective  Thyroid Surgeries.  
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GRANISETRON STRUCTURE 
 
 
                                                                   
  
              
 
  
 6 
     PHARMACOLOGY OF GRANISETRON 
 
Granisetron is a 5HT3 receptor antagonist,  clinically used as an                     
antiemetic   agent.                                                
DESCRIPTION: 
Granisetron   is   highly   selective   inhibitor   of   Type 3   serotonergic 
receptors or 5-hydroxytryptamine, (5-HT3) receptors. It has little or no 
action over the other types of   serotonin receptors. Granisetron  prevents 
nausea and vomiting induced by chemotherapy and radiotherapy. It has 
safety profile and well tolerated by the patients and   interactions   with  
other drugs  very  minimal, which makes Granisetron  is the drug of   
choice for elderly cancer patients to prevent vomiting. Granisetron  is 
crytalline solid  in nature and white to off-white in colour, which is 
freely soluble in water and 0.9% sodium chloride at 20⁰C and it is bitter 
in taste. Injection Granisetron hydrochloride  available  in 1mg or 2mg 
ampoules and as tablet 1mg or 2mg.                                            
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             MECHANISM OF ACTION 
 
Granisetron is   highly   selective   inhibitor  of  type 3  serotonergic 
receptors or -5-hydroxytryptamine,(5-HT3) receptors.  Granisetron   acts 
on the release of serotonin from the damaged   gastrointestinal mucosa   
of the enterochromaffin cells   following chemotherapy and 
radiotherapy.  5-HT 3 receptors situated on the afferent vagal nerves and 
in the brain. The 5-HT 3 receptors are   stimulated   by  serotonin 
released from the enterochromaffin cells which stimulates  the vomiting 
center in the brain through vagal afferent fibers and produce vomiting. 
Granisetron blocks the vomiting induced pathway by binding to 5-HT 3 
receptors and inhibit serotonin release. 5-hydroxytryptamine may 
influence both   heat production and heat loss pathways. Granisetron 
action on other types of serotonin  receptors are negligible. Other   types 
of   serotonin receptors are 5-HT, alpha1, alpha 2, and beta-
adrenoreceptors . 
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                                     PHARMACOKINETICS  
 
ABSORPTION:  
 Following oral administration Granisetron is completely absorbed and 
rapidly reaches the peak plasma   concentrations in 2 hours.  Oral   
bioavailability   is   complicated    by food, which  has  high intra- 
subject  and inter-subject  variability. 
DISTRIBUTION:     
Granisetron distributed in the   plasma in high   concentration. Freely 
distributed in the plasma red  blood cells also present. Volume   of   
distribution  is 2-3 L/kg.(12)  Onset of action is   within 1-3 minutes  of 
intravenous administration and which controls emesis. Duration of 
action is   upto  24 hours. Plasma   protein binding is approximately 
65%. Half-life   in    cancer    patients    is upto10 to 12 hours, and 3 to 4 
hours in healthy volunteers. 
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METABOLISM:    
 In the   liver   Granisetron is metabolized  by  various  changes such  as  
demethylation   and  oxidation  then end metabolites formed by 
conjugation, and these metabolites  also have some  antagonist activity  
on 5-HT3 receptor.  
ELIMINATION:  
Clearance of granisetron is predominantly by hepatic metabolism. 
Metabolites are excreted   in the urine and in the feces. Unchanged 
forms also excreted in the urine.   
USES :   
Prevention  and treatment of  
• Chemotherapy  and radiotherapy induced acute and delayed nausea 
and vomiting.  
• Post -operative   nausea and vomiting. 
 
CONTRAINDICATION: 
Hypersensitivity    to   Granisetron or   related   substances, or any other 
ingredient of the preparation. 
 10
ROUTES   OF   ADMINISTRATION: 
ORAL: Tablet 2mg/day or 1mg two times per day orally, one hour 
before cancer treatment either chemotherapy or   Radiotherapy 
INTRAVENOUS : 
40 µgm/ kg   body weight. 
 Dosage adjustments   are not   required   in hepatic dysfunction renal 
dysfunction  and  in   elderly patients.  
ADVERSE REACTIONS:  
Side effects >10%  1% - 10%  <1%  
Central nervous 
system  
headache  Asthenia, Dizziness, 
Anxiety,  
Somnolence, 
Agitation, 
Weakness  
Gastrointestinal 
system  
-  Loose motion , 
Constipation, and 
abdominal pain,  
-  
Haemtological 
system  
-  Blood pressure changes  -  
Cardiovascular system  Arrhythmias  
Endocrine / 
metabolic  
-  -  Hot flashes  
Hepato biliary 
system 
-  -  Liver enzyme 
may increase  
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STRUCTURE OF PETHIDINE 
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PHARMACOLOGY   OF  PETHIDINE 
Pethidine is a synthetic opioid which is used as an analgesic and   for 
prevention of postoperative shivering. Its actions are similar to 
Morphine.  
Description:  Pethidine   is  available as  Pethidine  hydrochloride.  
     
STRUCTURE-ACTIVITY RELATIONSHIPS: 
 The wide    array   of     different   molecules    that produce morphine 
like analgesia and    side     effects. Pethidine   is   a   phenylpiperidine 
derivative which presents with two rings in structure. First   totally 
synthetic opioid.  It has   an anticholinergic activity. But    was     found    
to   have     significant   analgesic    activity. It     has     moderate affinity 
for κ- and δ-opioid receptors has well-recognized weak local anesthetic 
properties. But   because of its local anesthetic effects, neuraxial   
Meperidine may also produce sensory and motor blockade as well as 
sympatholytic effects. There   effects are not seen with   other  opioids.  
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PHARMACOKINETICS 
Pharmacokinetics  of  the drug   is  described   by the following  four 
parameters: absorption, distribution, biotransformation, and excretion.  
Rate of elimination can be measured by clearance. 
ABSORPTION:  
Oraly  administered drug is absorbed well from the gastrointestinal tract.  
 Morphine is 10 times more potent than Pethidine. Following    
intramuscular injection   Pethidine   is absorbed  completely  into the 
plasma which reaches peak levels within one hour. 
DISTRIBUTION: 
Pethidine   is moderately lipid soluble, and is 40 to 70% protein bound, 
mostly to albumin and α1-acid glycoprotein. Following   intravenous 
administration, pethidine plasma concentration falls rapidly. As   the 
drug is distributed to extravascular sites, including sites of action and 
non - eliminating  tissues. Pethidine's redistribution half-life is 4 to 16 
minutes. Terminal   elimination half-life is between 3 and 5 hours. The   
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elimination half-life is not prolonged in elderly patients. In   neonates 
and infants, the median elimination half-life is 8 to 10 hours. Pethidine   
has   a large steady -state volume of distribution  in the range of 
 3.5 to 5 L/kg in adults.  
METABOLISM: 
 
 Pethidine  is  mainly metabolized in the liver by biotransformation 
which is converted into pethidinic acid by a process of hydrolysis and by 
conjugation with glucuronic acid. Which is converted  into  norpethidine 
by N- demethylation. Hepatic blood flow decides pethidine clearance 
because   it   has high hepatic extraction ratio. The   clearance about  
10 ml/kg/min. Pethidine’s end products can cause seizure due   to   
central nervous system   stimulation.  
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EXCRETION:  
Kidneys   mainly  removes the end products of  Pethidine. Through 
hepato  biliary  system about 10% eliminated.  Dose should be reduced 
in renal and hepatic impairment. Urinary   excretion may be enhanced by 
acidification   of  the urine.  
Physicochemical Characteristics and Pharmacokinetics 
s.no Parameter Pethidine 
1 pKa 8.5 
2 % Nonionized (pH 7.4) 7 
3 water partition coefficient 39 
4 Protein binding (%) 70 
5 Clearance (ml/min) 1020 
6 steady-state volume of distribution 305 
7 Slow redistribution half-life (T1/2π, min) 4-16 
8 Elimination half-life (T1/2β, h) 3-5 
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PHARMACODYNAMICS 
Drug action on   the   body described by  the following parameters 
1. Mechanisms  of action    
2. Drug  interactions,  
3. Structure– activity relationships.  
 
 MECHANISM OF ACTION: 
Opioid   receptors   are stereo specific in nature which are situated in the 
central nervous system , pheripheral  and spinal cord at presynaptic and 
postsynaptic areas. Endogenous   ligands  are usually binds to  opioid 
receptors. The   opioid  drugs  binds to  the receptor  on its anionic site 
and  mimics like a ligands following which alter the response of pain 
pathway. It will reduce the Neurotransmission by increasing   potassium 
conductance and inactivates calcium channel.   
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     EFFECTS OF DRUGS ON DIFERENT SYSTEMS 
 
THERMOREGULATION AND SHIVERING: 
Pethidine  is unique among opioids in its ability to effectively terminate 
or attenuate shivering. The effect of antishivering property is due to the 
reduction of   shivering threshold and   this   activity  mediated through  
the κ-receptor. However the relatively specific κ-receptor agonist 
nalbuphine did not show significant antishivering activity. Agonist 
activity at the α2B-adrenoreceptor subtype, suggesting possible action of   
Pethidine in the antishivering.  Alfetanil, Morphine, and fentanyl are not 
effective as Pethidinee in the prevention of shivering.  Tramadol 
(0.5 mg/kg) suppressed post epidural anesthetic shivering in parturients   
as effectively as Pethidine (0.5 mg/kg). But the incidence of somnolence 
was lower with Tramadol than with Meperidine. 
CARDIOVASCULAR SYSTEM: 
Meperidine   will   increase the heart rate   because  Pethidine  is 
structurally similar to atropine.   
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RESPIRATORY SYSTEM:  
Histamine  may  be  released  by  Pethidine    which  may cause  
bronchospasam in susceptible  individuals.  
ROUTES OF ADMINISTRATION AND DOSAGE:  
 
 
Dosage depends on patient profile  of  age, weight, sex, previous 
exposure to narcotics. 
 
PARENTRAL: 
  
1. Intramuscular 25 to 100 mg, every 3-4 hours.  
2. Subcutaneous25 to 100 mg,   every 3-4 hours.  
3. Intravenous   25 to 50 mg   slow IV injection, every 3 to 4 hours.  
4. Infusion 300µg/Kg weight/hour. 
For pain 10 -100 µg/Kg intravenously, for shivering 12.5-25mg 
intravenously. 
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CHILDREN:   
 Analgesia 50 to 200 µg/ kg   body weight intramuscular or 
subcutaneous. For    Preoperative 100 to 200 µg /kg body weight 90 
minutes before surgery. The   total dose should be 100 mg or less. If   
patients over 70 years of age dose   should   be reduced to   half   of its 
normal dose.  
DOSE CONVERTION: 
For analgesic effect of   intramuscular   Pethidine   of 75 to 100 mg  is 
equal to the   following drugs:  
• 10mg Morphine,  
• 200µg  Fentanyl,  
• 120mg Codeine Phosphate, 
• 8 to 10 mg Methadone Hydrochloride.  
    INDICATIONS 
• Short   term relief for moderate to severe pain.  
• Obstetric analgesia. 
•  Shivering. 
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    CONTRAINDICATIONS 
• Allergic to Pethidine. 
• Chronic lung disease with respiratory depression.  
• Head injury, raised ICT, brain tumor. 
• Arrhythmias like Supra ventricular tachycardias, 
• Patients on  monoamine oxidase inhibitors.   
• Toxaemias of Prgnancy, 
• Seizure disorders and tetanus, 
• Metabolic encephalopathy and Diabetic coma, 
• Alcoholic intoxication, 
• Liver failure and   
• Renal  impairment  
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ADVERSE REACTION: 
RESPIRATORY SYSTEM: 
Impairment  of respiratory  function is  the most common side effect of 
Pethidine. 
CENTRAL NERVOUS SYSTEM: 
 Lightheadedness,  
Dizziness ,  
Sedation ,  
Abnormal   feelings, 
Dimnised orientation, 
Psychological  problems.  
 
GASTROINTESTINAL  
Nausea   and Vomiting,  
Abdominal   discomfort and   constipation. 
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 CARDIOVASCULAR SYSTEM:  
Complications are less common 
 It may increase or decrease blood pressure leads to  Hypertension or 
hypertension respectively, vasodilation, ,heart rate changes either 
tachycardia or  bradycardia. 
Dermatological complications are also less common, which are   Rash, 
Pruritus,  Urticaria  and  Erythema. 
 INJECTION SITE COMPLICATION 
Local   irritation and induration and fibrosis of muscle tissue with  
frequent  repetition of intramuscular injection. 
RENAL:  
 Retention   of urine   and with oliguria and anuria. 
HEPATOBILIARY SYSTEM:  
• Increased biliary tract pressure,  
• Coledochoduodenal sphincter  spasam.  
Neuropsychiatric  toxicity. 
 Additive  Potential 
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OVERDOSAGE 
Symptoms:  
Bradycardia   and hypotension, peripheral   cold clammy skin and   
hypothermia   leads  to shock. Altered   sensorium to  coma due to 
central nervous system    depression. Respiratory   failure due to   
depression,   skeletal  muscles   weakness.  Apnoea , circulatory 
collapse, cardiac arrest, respiratory arrest and death seen in severe over 
dosage. Pneumonia, shock, pulmonary oedema,   severe hypoxia and 
terminal narcosis. If   Normeperidine   concentration in  plasma   is more  
than 0.81 µg/ml patients usually develops   seizure .      
INCOMPATIBLITES: 
Inactive   complex formed by Pethidine   while   mixing with   
Thiopentone.  
Clarity of solution was lost when combine with Aminophylline.  
 Which also becomes incompatible when combined with following   
drugs  Methicillin sodium, Morphine sulphate, Heparin,Phenobarbitone 
sodium, Phenytoin sodium, sodium bicarbonate , sodium iodide and  
alkalis. 
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INTERACTIONS WITH OTHER   DRUGS: 
 
The CNS depressant effects of Barbiturates, chloral hydrate, 
benzodiazepines increased   by pethidine, and analgesic effect of 
pethidine    reduced when given along with   these drugs. 
Phenothiazines: CNS toxicity     hypotension and respiratory 
depression.  
Butyrophenones: The CNS depressant effect of tranquillisers   is 
increasd. 
 When combined  with Monoamine oxidase inhibitors can cause  
hypertension or hypotension, Excitation, sweating, rigidity and  coma.  
Phenytoin: 
 Which  increases the   toxic metabolites of pethidine and increased CNS 
toxicity and reduce the  analgesic effects. 
Pethidine   will increase the  anticoagulants effects  Coumarin  or 
Indandione .  
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                                   THERMOREGULTION  
 Body temperature is determined by the relationship between heat 
production as a product of   metabolism and heat loss to the 
environment. Body   temperature   is regulated and maintained within 
narrow limits   between 36.7 to 37.5°C   by  the adjustment of heat 
production  within the  body and heat loss from the body into the 
environment. Temperature   is lowest in the morning and highest in the 
evening. During sleep there is consistently decreased a 10% to 15% in 
the basal physiologic metabolic rate, presumably reflecting the 
decreased activity of skeletal muscles and the sympathetic nervous 
system.  
HEAT LOSS:  
Heat loss from the body occurs by the following mechanism of 
radiation, conduction, convection, and evaporation. Under typical 
circumstances most heat (~60%) is lost by radiation.  Contact with a 
cooler object and administration of cold intravenous fluids and blood 
products results in reductions in core temperature due to conductive 
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losses. The rate of convective loss depends on both the temperature   and   
velocity   of air in the environment this mechanism known as the wind-
chill phenomenon. The   body can eliminate excess   heat   when the 
temperature of the surroundings is higher than that of the skin by the 
mechanism of evaporation. With continued exposure to a warm 
environment, sweat production may be increased upto 1,500 ml/hour. 
Two -thirds of the heat   loss from the   respiratory  tract  by evaporation. 
 INTERTHRESHOLD RANGE:  
Interthreshold   range is   a  range at   which the   core  temperature will 
not trigger   autonomic     response which  is a few  tenths of  a   degree 
Centigrade.  This    range is bounded   by sweating   threshold   in the 
upper end   and  vasoconstriction in  the lower end.  
GAIN: 
The changes   in the   slope   of   response   intensity  in relation to  Core  
temperature     defined   as  the gain of a thermoregulatory response.  
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MAXIMUM  INTENSITY:  
 The intensity   of the response no longer  increasing in relation to   
further deviation in core temperature which is known as maximum 
intensity. 
PHYSIOLOGY OF THE TEMPERATURE   REGULATION  
Thermoregulatory responses are graded, and each particular   response   
is   characterized  by   a  threshold  temperature  at which  it  is  initiated. 
In   humans  normal  core temperature regulated tightly within narrow 
range between  36.7 to 37.1°C.  Vasoconstriction  in response to cold 
occurs at 36.5°C whereas shivering occurs when  core temperature drops 
below to 36.2°C. 
There are three components that govern the physiology of 
thrmoregultion 
1.Afferent neural pathway 
2. Central regulation 
3. Efferent response pathway 
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Following   thermal information core body temperature is maintained 
within narrow therapeutic range by modulation and integration of  these  
Components. Behavioral  regulation  is the most important  effector 
mechanism in conscious patients. Behavioral compensations includes 
appropriate dressing, environmental temperature modification, assuming 
positions that oppose skin surfaces, and voluntary movement. 
AFFERENT NEURAL PATHWAY: 
 
Thermal sensation received from thermal receptors located in the 
periphery which are presented both in the central as and peripheral areas. 
There are two types of themal receptors for warm and cold sensation. 
Cold signals pass through  delta fibres and unmyelinated C fibres 
transmit the warm signals.Spinal cord are thermosensitive which  
integrate and modulates thermal inputs  from  thermal fibers. Through  
lateral spinothalamic tracts  information reach the hypothalamus. 
shivering  response inhibited by  nucleus raphe magnus,  shivering 
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response increased by locus subcoerulus neurons. Both  of  which relays   
information to hypothalamus from skin. The   entire spinal  cord must be 
destroyed for loss of all  thermoregulatory  responses. Total   thermal   
input to the central regulatory system from several regions of the body   
each contribute 20% of the input. The  hypothalamus  and  other  parts  
of  the  brain,  spinal cord,  deep abdominal , thoracic tissues and the 
skin surface. According to recent several special thermoreceptors were 
present in the skin and dorsal root ganglia. Special  receptors are 
transient receptor potential,vanilloid ,and menthal receptors which are 
thermosensitive.Transient  receptor potential,vanilloid are activated by 
heat, menthal receptors are activated by cold. 
CENTRAL CONTROL  
Body  temperature is regulated by the feedback mechanisms  of  the 
anterior hypothalamus  that are operated predominantly through   
preoptic  nucleus .  
1.The anterior hypothalamus-  
preoptic region is an important central regulator, 
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2. Brainstem  also subserve this function  
3.Spinal cord. The  thermostat  warm neurons  of hypothalamus   detects 
body temperature changes and compare the triggering core temperatures 
thresholds of  afferent pathway. Then   integrates this information  and  
initiates thermo regulatory  responses which are autonomic, somatic, and 
endocrine responses when the various set points are reached. The  
Anterior hypothalamus controls the information received from the 
central structures. Posterior   hypothalamus  controls the behavioural 
responses. Information  from the skin surface reach the posterior 
hypothalamus.The effector responses are  different according to their  
interthreshold temperature. Serotonin,acetylcholine and prostaglandin 
modulates the inhibitory potentials of hypothalamus.Threshold 
temperatures  are changed  daily in cyclical  pattern known as  circadian 
rythm  variation between 5 to 10 C and   The  interthreshold range  is 
between 0.2 to 0.40C which is0.3 to 0.50C higher in women than men. 
The shivering threshold is poorly regulated in the elderly.                        
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                  EFFERENT  RESPONSE PATHWAY 
 
Common   efferent pathway achieve optimal  thermoregulation through  
integration of multiple inputs from afferents in an orderly fashion.  
Efferent responses are either increase heat  loss or promote heat gain  
based on thermal disturbances Each response is    governed by a specific 
threshold.The  principle  protective mechanisms  against  hypothermia   
includes, Thus   shivering is the “last resort” of  activity following 
hypothermia. The body temperature to be maintained at a value for 
optimum enzyme activity for a constant rate of   metabolism, optimal 
nervous system conduction, and skeletal muscle contraction. 
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cold response below 36.50C 
 
Warm  response above 37.50C 
Vasoconstriction 
 Shivering  
Non  Shivering 
 
 
Vasodilation 
Sweating  
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NONSHIVERING THERMOGENESIS: 
 Brown fat produce heat by  cellular metabolism without muscle activity  
which is known as chemical thermogenesis or nonshivering   
thermogenesis. Sympathetic nervous system stimulates heat production 
by circulating Catecholamines without increasing mechanical work. 
Which has been demonstrated in  infants.  The Chemical thermogenesis 
can increase the rate of heat production by as much as 200% in infants 
Shivering is not well developed in newborn infants.. 
SHIVERING THERMOGENESIS:  
Initially core body temperature is increased by behavioral response, 
vasoconstriction and peripheral arterio-venous shunting of blood.When 
these measures failed shivering is last response to generate heat by 
increasing muscular activity. The vasoconstriction threshold is an 
entirely 10 C more than the shivering threshold. Decreased    core 
temperature can  cause shivering   by which to increases the  body  heat 
production. The posterior hypothalamic area responsible for the response 
to  hypothermia.  
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PHYSIOLOGY  OF  SHIVERRING 
1. Thermoregulatory  response due to hypothermia, 
2. Inflammatory   response due to release of cytokines, 
3. Loss  of autonomic thermoregulatory functions,  
4. Postanesthesia   shivering. 
DEFINITION   
 Shivering is  defined as, spontaneous, , oscillatory and  an involuntary 
mechanical  activity of skeletal muscle associated with an increased  
oxygen  consumption   by 600% (19) above the baseline . 
 CLASSIFICATION  
Depending on the thermoregulation shivering is are classified  into two 
Types: 
1.Thermoregulatory and  
2.Nonthermoregulatory in nature.  
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THERMOREGULTORY SHIVERING : 
In  hypothermia Shivering occurs for heat production  to maintain  
normothermia if  vasoconstriction response is inadequate. 
NON   THERMOREGULTORY SHIVERING:  
Non thermoregulatory shivering in normothemic individuals includes   
 1. Pain after surgery, 
 2. Endogenous pyrogens release, 
 3.Uninhibited spinal reflexes, 
 4. Adrenal suppression and  
5. Labour and delievery. 
 RISK FACTORS: 
 
1. Male  gender,  
2. Prolonged surgeries and ,   
3. Anaesthesia,  
4. Younger age groups. 
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 GRADING OF SHIVERING :  
Shivering scale validated by Tsai and Chu 
The  intensity of  postanaesthesia shivering graded according to the 
involvement  muscle groups ,severity of shivering grded from Grade 0 to 
Grade 4. 
 
GRADES:  
 
  0  No shivering activity, 
 
1 
 
 Only piloerection and vasoconstriction, 
 
2 Involving only one muscle group, 
3 More  than  one muscle group but no generalized shaking 
4. Generalized the whole body involved. 
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PATTERNS OF SHIVERING: 
According to the nature of shivering   which is classified into two  
patterns. General anaesthesia has two patterns of shivering  and also 
confirmed of EMG assessment. 
 
FIRST PATTERN:  
Seen in Thermoregulation shivering as  a synchronous ”waxing and 
waning” pattern.and frequency is about  4 to 8 cycles  per min and  
which is tonic in nature.this patterns also seen  volunteers who exposed 
to cold enviroments. 
 
 
 
 
 
 
                                  EMG –TONIC –PATTERN  SHIVERING 
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SECOND PATTERN:  
Shivering is clonic in nature at frequence rate   of 5-7Hz. As  seen in 
spinal cord transection with uninhibited  spinal reflexes. Also  seen in a 
study of isoflurane with 0.2-0.4 end-tidal concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
EMG – CLONIC-PATTERN SHIVERING 
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MECHANISM OF SHIVERING 
 
The shivering motor centre situated in   the  posterior  hypothalamus is 
stimulated when the  temperature of Preoptic areas is  very cool. 
Temperature   changes  produced in neuronal activity in  mesencephalic 
reticular formation and dorsolateral pontine and medullary reticular 
formation by effector  pathway of  shivering descends  from the 
posterior hypothalamus , and    muscle tone increasd by α motor neurons  
common pathway. shivering  occurs  when     muscular activity is  
increased. Through   renshaw  cells, a group of inhibitory interneurons  
mediate the shivering  by recurrent inhibition. Three   compensatory 
defence mechanisms to counter hypothermia and prevent    subsequent 
heat loss by the  following 
1. Vasoconstriction, 
2. Heat production  without shivering, 
3. Heat   production  by   muscle shivering. 
Skeletal muscle shivering is one of the mechanism that, can   be  treated  
and can be prevented.          
 40
 
PREVENTION OF POSTOPERATIVE SHIVERING: 
 Shivering can be prevented by two methods  
1. Non  Pharmacological   
2. pharmacological by drugs 
   
PREVENTIVE MEASURES: 
The   dictum is always prevention(3)is better than cure. This    dictum can 
be applied for prevention of postoperative shivering. Most authors also 
suggested  the importance of prevention of hypothermia during  surgery.  
NONPHARMACOLOGICAL : 
 Increasing the skin temperature and  decreases the temperature gradient 
between the central and peripheral compartments by the following 
methods ,such as increase the operation room ambient temperature,  
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Which   prevents external cooling of the body,  Preventing  heat loss 
from the body by convective mechanism of heat loss which can be done  
by insulation  methods like   external warming with  cotton blankets and 
use of warm skin disinfectant. Internal warming with   use of warm 
intravenous fluids and warm Local anaesthetics for neuraxial blockade. 
These   measures increase the skin temperature  without   change in core 
body temperature and prevents internal heat redistribution. During   
anaesthesia intra compartmental heat changes due to vasodilation   
which heat transfers from periphery to central   than postoperative 
warming for the prevention of postoperative  shivering.  Cutaneous   loss 
can be prevented by insulation method which prevents about thirty 
percent. By all these measures core temperature should be   maintained   
more than 36⁰C.  
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PHARMACOTHERPY: 
Several   drugs  are   used  for the prevention of shivering. 
MECHANISM OF ACTION  
For the prevention of shivering central thermoregulatory   mechanisms 
should be modulated  and  modifying  shivering adaptive  threshold. 
when core temperature decreased 5-HT induce   shivering and 
vasoconstriction which leads to increase core temperature. Adaptive 
mechanism modification responded to the balance between 5 HT and 
Noradrenaline. By inhibit the synaptosomal uptake of 5-HT and 
Noradrenaline prevent shivering .Shivering and vasoconstriction induced 
by Acetylcholine and nicotine. When   preoptic   area is cooled the 
Acetylcholine release is   increased to about 88(3) percent. During 
warming Acetylcholine release(3) is suppressed to 80 percent. 
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The following drugs are used for prevention of shivering 
1. Pethidine - κ  receptor agonist, 
2. Tramadol  – opioids , 
3. Clonidine  -central α2 –adrenergic agonist, 
4. Ketamine - N-methyl-D- aspartate receptor antagonists , 
5. Magnesium sulfate-physilogical  NMDA receptor antagonists, 
6. Physostigmine -  centrally acting cholinesterase inhibitor, 
7. Granisetron -5HT3 antagonist. 
TEMPERATURE MONITORING 
 
Human body temperature is   heterogeneous   in   nature, core 
temperature is always higher than peripheral temperature the difference 
between 2 to 40C. Deeper      structures are   always warmer   than 
peripheral   structures. Temperature monitoring is very much important 
for prevention of hypothermia before onset of shivering. Skin 
temperature usually varies.  Measure of Core temperature is the gold 
standard for temperature monitoring. 
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MONITERING   SITES FOR CORE TEMPERATURE: 
 
1. Tympanic membrane,  
2. Pulmonary  Artery,  
3. Nasopharynx,and  
4. Oesophagus  distal part. 
NEAR CORE TEMPERATURE SITES: 
Mouth, Axillae, Bladder, Rectum and Skin surface. Each site and 
modality of monitoring has its own limitations, which should not exceed 
0.50C level of inaccuracy. 
METHODS OF  MEASUREMENT : 
1. Most   accurately measured by Infrared Thermometers and which are 
inexpensive.  
2.  Tympanic probes are   being soft and pliable. Disadvantages are     
risk of  perforation,  and incorrect position. 
3.Oesophageal  probes  incorporated into oesophageal stethoscopes 
which  are safe  and accurate when positioned into the distal 
Oesophagus. 
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4. Nasopharyngeal  probes are best placed a few centimetres  distal to 
the nares adjacent to the Nasopharyngeal mucosa.  Risk  of epistaxis  
when  trauma occurs during insertion. 
Oral, Axillary, Bladder and Rectal Temperature can measure Core 
Temperature with fair accuracy in the absence of extreme temperature 
disturbances.  
MECHANISM OF HYPOTHERMIA UNDER ANAESTHESIA 
 
1. Thermoregulation  impairement  during  anaesthesia, 
 
2. Heat redistribution from the core to pheriphery 
 
 
3. Lower ambient temperatures, 
 
4. Cold intravenous fluids, 
 
     5.  Heat loss from surgical sites. 
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GENERAL ANAESTHESIA: 
 
The defence mechanisms of thermoregulation  is impaired   resulting in  
heat redistribution from core to the peripheral areas which leads to 
hypothermia.  
 During  general anaesthesia core temperature changes  occur in three   
phases. 
 
Phase 1- Rapid fall in   core body temperature occurs   during the first 
hour of anaesthesia  from 1-20C due to heat redistribution. 
  
Phase 2- Next 3-4hrs the core temperature fall is gradual due to   the 
environment heat loss.  
Phase 3- Following   phase -2 an equilibrium achieved between heat 
loss and production.  
 General anaesthesia  the interthreshold range increased from 0.2 – 0.40C 
due to  thermoregulation impairment which limit the thermal  defence   
responsiveness. After extubation  interthreshold range is return to 
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normal which cause normal thermoregultory  response to hypothermia 
and cause shivering. 
 
  
 
 
Hypothermia in general anaesthesia
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Thermoregulation   thresholds in   unanaesthetised and 
anaesthetised humans.  
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NEURAXIAL ANAESTHESIA:  
 
 Above   the level of the  Neuraxial blockade vasoconstriction and 
shivering occurs  due to  thermal defence mechanism. Inadequate in 
generating metabolic heat as the muscle mass cephalad to the block is 
small.  Similar mechanisms surround with the 
Phase 1 - Fall in core body temperature due to internal heat   
redistribution  by vasodilatation . 
 Phase 2-   continuous heat loss occurs thermoregulatory centre is 
sensed by the normal unblocked area.  
 Hypothalamus   sensed by the elevation of skin  temperature above the 
blockade area which results in altered perception of temperature  results 
in decreasing  shivering threshold below the blockade area. 
Vasodilatation produce ongoing   heat   loss at below the level of   the  
blockade which  results in risk of undetected hypothermia until shivering  
occurs. Shivering threshold in epidural anaesthesia being directly related 
to the number of dermatomes blocked. Sacral   nerve roots spared which 
results in   reduced thermal afferent input and shivering threshold.  In 
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Spinal anaesthesia associated with complete motor blockade. The 
difference between these will be postulated that the epidural and intra 
thecal space differ in terms of thermo receptors and their respective 
sensitivity.   
 
ADVERSE EFFECTS OF SHIVERING      
1.Patient discomfort also has several deleterious effects.  
 
2. Difficulty with monitoring techniques. 
  
3.Increased oxygen consumption and metabolic demand. 
 
4.Increased introcular and intracranial pressure. 
 
5. Metabolic acidosis. 
 
6. Increased carbon dioxide production. 
 
7.Increased post-operative pain from surgical incision stretching. 
 
8.Increased in cardiac output. 
 
9. Increased minute ventilation and systemic vascular resistence 
  
10.Raised plasma catecholemine levels . 
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Post anaesthesia shivering is predominantly thermoregulatory in nature 
as  a result of the anaesthetic induced inhibition of thermal defense 
mechanisms and subsequent hypothermia.  
 
HYPOTHERMIA:  
 
 Is  a core temperature greater than one standard deviation below mean 
core temperature for that mammal under resting conditions.  Mild   
hypothermia is defined as  a  core body temperature of between 33.0 – 
36.40C, at which cellular and tissue dysfucntion may develop.During 
periods of cerebral or cardiac ischaemia, it is thought that hypothermia 
maybe protective on the basis on decreased metabolic demand,however 
hypothermia should be considerd  in anaesthesia, depends on the risk 
benefit ratio.  
 
 
 
 
 52
 
 
Adverse effects of Mild hypothermia    
 
1. impaired immunity and surgical site infection, 
2.  delayed wound healing,  
3. coagulopathy,  
4. increase in allogenic blood transfusions,  
5. delayed post anaesthetic recovery,  
6. prolonged hospitalistion,  
7. patient discomfort, and 
8.  morbid myocardial outcomes  
9.   secondary to  increased plasma catecholemines.        
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                                  REVIEW OF LITERATURE  
 
 
1.Asif Iqbal ,et.al,(1) 
 in 2009 conducted a  study to  compare the effectiveness of the drugs 
Pethidine and Granisetron for the prevention of postoperative shivering 
in patients undergoing laparoscopic surgery under general 
anaesthesia.90  patients aged 20-60yrs, ASA /PS  I and II, they  were 
randomly allocated to three groups  receive either normal saline S  as 
negative control, Pethidine 25mg  as positive control or Granisetron 
40µg/kg  intravenously before  induction. Nasopharyngeal temperature 
was measured throughout the procedure. An investigator blinded to the 
treatment group, graded postoperative shivering in a scale of 0 to 4. In 
this study, they   found that Granisetron 40 microgram /kg  was as 
effective as inj.Pethidine 25mg in preventing shivering  after general 
anaesthesia. 
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2.D. Dal,et.al (2) 
In 2005 done a study to  compare the efficacy of low-dose prophylactic 
Ketamine with that of Pethidine or placebo for the preventing of 
postoperative shivering in patients undergoing general anaesthesia. A 
prospective randomized double-blind study enrolled  90 ASA I and II 
patients undergoing general anaesthesia. Patients were randomly 
allocated to three groups  each groups enrolled 30 patients randomly 
receive normal  saline  , Pethidine 20 mg  or Ketamine 0.5 mg/ kg drugs 
were  given  intravenously 20 min before completion of surgery  In their  
study, none of the patients shivered after prophylactic Pethidine. In this 
study, they  found no difference between the efficacy  of Ketamine and 
Pethidine in preventing postanaesthetic shivering.  
  3.Masood Entezariasl,et.al (22) 
 In 2012   this double-blind clinical trial study was carried out on 120 
patients who were  posted  for surgery under general anesthesia. The 
patients were randomly divided into three groups. Induction and 
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maintenance of anesthesia for all patients were similar. Temperature of 
patients was measured every 5 min interval. After induction, saline0.9%, 
Dexamethasone and Pethidine were injected to groups a, b, and c 
respectively. In recovery, patients were controlled for visible shivering. 
Considering the fact that injection of dexamethasone after induction of 
anesthesia has been able to reduce the postoperative shivering from 
47.5% to 10%, and  reduction of postoperative nausea and vomiting in 
the use of the drug, dexamethasone can be used as an alternative to 
administration of pethidine  particularly in patients with hemodynamic 
instability.   
4.  BY JEAN-DENIS ROY,M (23) 
 
 In 2004 volume 3, issue 6 of Anesthesiology Rounds endeavours  
explained postoperative shivering  pathophysiology and discussed  
preventive strategies and treatments. postanesthesia shivering may not 
just be a thermoregulatory reaction .Shivering may be  one manifestation 
of an inflammatory response.  Powell and Buggy studied Ondansetron, a 
5-HT3 antagonist and   found that an intravenous dose of 8 mg a just 
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prior to the induction of general anesthesia significantly reduced the 
incidence of postoperative shivering. This effect is probably due to a 
central inhibitory mechanism, given that there was no measurable effect 
on heat redistribution. These observations suggest that the serotoninergic 
pathways play a significant role in the regulation of postoperative  
shivering. 
 
5.Dr. Pradip K. Bhattacharyaet.al(3) 
 
  
In 2003 reviewed The physiology of PAS, organisation  of the 
thermoregulatory mechanism, various measures for prevention and the 
methods both  pharmacological and non pharmacological, of effective 
managements  in this article.  In homeothermic species, a 
thermoregulatory  system coordinates defenses against environmental 
temperature to maintain internal body temperature within a narrow range 
Since shivering is an accompanying part of  general and regional 
anaesthesia and it leads to various  consequences and discomfort to the 
patient, proper steps must be taken for its prevention and treatment. The 
 57
most effective measures for prevention and treatment are forced air 
warming and fluid warming. The pharmacological agents for combating 
it are Nefopam, Tramadol, Physostigmine, Morphine, Fentanyl, and 
Pethidine etc.As the dictum says, “prevention is better than cure”it holds 
true for shivering also and it should be practiced. 
 
6.M Entezari Asl, et.al  
 In   2008. at  Alavi University Hospital ofArdabil . They conducted 
study to  see  Effect of Ondansetron in  Prevention  of  Postoperative 
Shivering after General Anesthesia  in Gynecological Surgery  they 
selected all patients were in ASA physiologic class I or II.  They were 
randomly selected to receive either 4 mg ondansetron, 0.4 mg/kg 
Meperidine  or 2ml normal saline 2 minutes before inducting anesthesia. 
They monitored temperature through tympanic membrane. They   were 
observed for shivering.  At the end of study they suggested that  using 
Ondansetron instead of  Meperidine is better  because of its ability to 
reduce shivering  from 50 to 13.3% in addition to  reduce  vomiting and 
lower side effects especially in patients with homodynamic instability. 
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7.H. Alex Choi et.al  
 
In  2010 they conducted the study of aggressive temperature control 
method The Columbia Anti-Shivering Protocol for Prevention of  
Shivering  During Therapeutic Temperature Modulation  to  avoid  the 
negative consequences of many anti-shivering therapies. They  have 
developed a stepwise protocol that emphasizes use of the least sedating 
regimen to achieve  adequate shiver control. Methods all patients treated 
with temperature modulating. At the end of study they concluded   that  
significant proportion of patients undergoing temperature modulation 
can be effectively treated for shivering without over-sedation and 
paralysis. Patients at higher risk for needing more interventions are 
younger men with decreased body surface area. 
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                        METERIALS  AND METHODS   
 
This study was approved by institutional Ethical committee of Madras 
Medical College  Chennai. The  study  was  A Prospective Randomized 
Double Blind Study to Compare  the Effectiveness of Prophylactic  
Granisetron versus Pethidine, for the Prevention  of Post operative 
Shivering in Patients undergoing Elective Thyroid  Surgeries. Informed   
consent obtained from patients regarding study. 
INCLUSION CRITERIA:    
• Age       : More than 18 years  
• Weight  : 40 -70Kg 
• ASA      : I  and II 
• Surgery  :Elective Thyroid surgeries 
• Who have given a valid informed consent 
• Duration of surgeries less than  3 hours 
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EXCLUSION CRITERIA: 
           Not satisfying the above said   inclusion criteria 
•  Patients with cardiopulmonary diseases 
•    Psychiatric diseases 
• Patients  who require blood or blood products 
INFORMED CONSENT: 
Before enrolment all the patients were explained about   the nature of the 
study fulfilling selection criteria and the intervention after   that   
informed written consent obtained. 
METHOD OF COLLECTION OF DATA: 
The patients satisfying   inclusive criteria were explained in a detailed 
manner   about the study and procedures and expected side effects.  
After   that   informed written consent obtained from the patients. They   
were clinically reassessed. Age, sex, height, and weight  were noted. 
Baseline vitals   like pulse, blood pressure, were noted. Blood sugar, 
complete blood count, blood urea, serum creatinine, bleeding time, 
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clotting time, ECG, and chest X-ray were cheked.  Airway  assessment 
done  then all  systems were thoroughly examined.  
  MATERIALS  REQUIRED:    
Nasopharyngeal Temperature probe,   
 Drugs: InjPethidine , Inj.Granisetron.,  Inj.Glycopyrrolate, 
Inj.Fentanyl,  Inj.Thiopentone sodium,   
Inj.Atracurium Besylate,  Normal Saline, 
 Sevoflurane,    and   Emergency drugs. 
  
 MONITORS:  
 ECG, SPO2, NIBP, ETCO2  and Temperature Probes. 
RANDOMIZATION: 
90 Patients were randomly allocated into three groups – group P,  
group G , group S in each groups thirty patients were selected  
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Group P (n=30)   patients   were given Inj.Pethidine 25 mg 
intravenously 5 minutes  before induction of general anaesthesia. 
Group G (n=30)   patients  were given  Inj.Granisetron 40µgm/Kg 
intravenously 5 minutes   before induction of general anaesthesia. 
Group S Placebo (n=30)  patients  were given  Normal Saline 
intravenously 5 minutes  before induction of general anaesthesia. 
 
PRIMARY OUTCOME MEASURES:    
•  Post operative shivering  score 
• Temperature , (Core and peripheral), 
• Systolic blood pressure,  
• Diastolic blood pressure,  
• Mean Arterial Pressure  ,   
• Heart rate and 
• SPO2   
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Changes  during intra operative and post operative period. 
 
SECONDARY OUTCOME MEASURES:  
• Post operative  Pethidine  requirement,  
• Nausea    
• Vomiting    
• Tachycardia   / Bradycardia 
• Hypotension      
• Desaturation 
 
 PROCEDURE:  
After   the nil per oral confirmed, Monitors  ECG, NIBP, Pulse oximetry 
are connected, Nasopharyngeal Temperature probes, Surface 
Temperature probes were applied after application of lignocaine gel. 
Base line parameters were noted. Patients were   started   with 
crystalloids  after intravenous line secured with appropriate intravenous 
cannula.  Heart rate, Temperature (Core and peripheral, OT),   
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Noninvasive   blood pressure (SBP,DBP,MAP)  and SPO2    were noted. 
Then  study drug  were given intravenously 5 minutes before Induction   
of anaesthesia  all  the patients were  monitored  intra operatively and 
after extubation  in the recovery room, for   30 minutes  patients received  
oxygen through facemask. The patients were observed for shivering, 
pain, nausea and vomiting of the study drug. Heart rate, non-invasive 
blood pressure, oxygen saturation and nasopharyngeal temperature were 
measured and recorded on admission to the recovery room at 15 and 30   
minute interval. The shivering was graded and side effects were 
recorded.   
Patient with nausea and vomiting were treated with Metoclopramide 
10mg slow IV.  
Shivering   grade 3 or more treated with Pethidine 25 mg intravenously.  
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Grading of   shivering   was done by scale validated by Tsai and Chu 
 GRADES:          
• 0 - No shivering, 
• 1-Piloerection ,no visible shivering, 
• 2- Muscular activity in only one group,  
• 3- Muscular activity in more than   one group  but not generalised   
• 4- Shivering is   generalised   involving whole body. 
STATISTICAL ANALYSIS 
All parameters were  analysed using SPSS 20.0 for windows. These data 
were compared among three groups using one way ANOVA. The 
incidence of shivering and side effects were compared using Chi-Square 
test. The data comparison within the groups were analysed using 
Bonferroni´s post-hoc testing. The data was expressed as mean ± 
standard deviation 
A  P value <0.05 was considered statistically significant.  
A  P value >0.05 was   considered  statistically   insignificant. 
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                       OBSERVATION AND RESULTS 
 
 A Prospective, Randomized Double Blind Study to Compare  the 
Effectiveness of Prophylactic  Granisetron versus Pethidine, for the 
Prevention  of  Postoperative Shivering in Patients undergoing Elective 
Thyroid  surgeries. The study was conducted in 90 patients. All   were 
female.   All the patients completed the study.  
 
There was no difference between the three groups with respect to age, 
sex, height, weight and procedure. The P value was insignificant  
For age (P-0.83), for height (P-0.47),   for weight  (0.16).These  values 
shown in following tables.      
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DEMOGRAPHIC PROFILE 
TABLE- 1                     Weight (in Kgs) 
Group Mean Standard Deviation 
GROUP-I 55.73 5.36 
GROUP-II 54.23 3.72 
GROUP- III 56.67 5.47 
F-value  1.87 
p-value 0.16- Not Significant 
 
TABLE-2  Height (in centimeters) 
Group Mean Standard Deviation 
GROUP-I 154.57 3.36 
GROUP-II 154.10 3.69 
GROUP- III 155.23 3.60 
F-value  0.77 
p-value 0.47 
Significant Not Significant 
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TABLE-3   MEAN AGE (in years) 
Group Mean Standard Deviation Range 
GROUP-I 46.87 9.94 22 - 60 
GROUP-II 45.83 7.92 32 - 59 
GROUP- III 45.47 9.41 26 - 59 
F-value   0.19 
p-value                      0.83                  -            Not Significant 
 
 
BASE LINE VITALS:  
Base   line vitals   of three groups were compatible . The   P-values of 
Heart rate, SBP, DBP, MAP, and   SPO2   were   insignificant between 
three groups. These values are shown in following tables. The P   value  
of Heart rate, SBP, DBP, MAP, and   SPO2 were  0.45, 0.14, 0.07, 0.15 
respectively. 
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TABLE .4     Hart Rate  
Group Mean Standard Deviation 
GROUP-I  5.62 
GROUP-II 78.73 5.72 
GROUP- III 80.33 6.08 
F-value  0.81 
p-value 0.45 - Not Significant 
 
TABLE-5 
Systolic Blood Pressure  
Group Mean Standard Deviation 
GROUP-I 127.50 7.73 
GROUP-II 127.50 8.47 
GROUP- III 124.00 7.30 
t-value  1.99 
p-value 0.14 
Significant Not Significant 
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SYSTOLIC BLOOD PRESSURE 
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TABLE-6 
Diastolic Blood Pressure  
Group Mean Standard Deviation 
GROUP-I 77.67 5.76 
GROUP-II 80.87 7.82 
GROUP-III 77.07 6.39 
F-Value 2.78 
p-value 0.07 
Significant Not Significant 
 
TABLE-7. Mean Arterial Pressure  
Group Mean Standard Deviation 
GROUP-I 92.10 6.48 
GROUP-II 95.27 8.57 
GROUP-III 92.27 5.48 
F-value  1.97 
p-value 0.15  - Not Significant 
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BASE LINE TEMPERATURES 
Base line temperatures of core, surface, and OT were recorded. 
Stastically   the P-values were insignificant between three groups. 
These values were shown in the following tables. 
 TABLE-8   CORE TEMPERATURE 
Group Mean Standard Deviation 
GROUP-I 36.64 0.12 
GROUP-II 36.67 0.12 
GROUP-III 36.67 0.11 
F-value  0.75 
p-value 0.48 
Significant Not Significant 
 
TABLE-9  OT  TEMPERATURE 
 
Group Mean Standard Deviation 
GROUP-I 22.41 0.16 
GROUP-II 22.41 0.16 
GROUP-III 22.38 0.15 
F-value  0.39 
p-value 0.68 
Significant Not Significant 
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TABLE-10            SURFACE TEMPERATURE 
Group Mean Standard Deviation 
GROUP-I 36.59 0.14 
GROUP-II 36.58 0.13 
GROUP-III 36.61 0.13 
F-value  0.39 
p-value 0.68 
Significant Not Significant 
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The OT temperature P value 0.68, surface temperature value  
P-0.68 and core temperatures P value 0.48 insignificant were 
comparable between three groups. 
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TABLE-11INTRA OPERATIVE HEART RATE /min 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 79.50 5.84 82.13 5.88 80.57 4.49 1.78 0.18 
30 80.63 6.20 80.20 5.52 78.83 3.89 0.95 0.39 
45 81.57 4.77 79.13 5.08 81.53 4.65 2.50 0.09 
60 82.07 4.86 82.13 5.88 82.47 4.47 0.05 0.95 
75 81.97 5.63 79.90 4.35 81.27 6.14 1.13 0.33 
90 81.57 4.77 79.97 4.52 80.43 5.46 0.84 0.44 
105 80.73 4.65 80.13 4.81 79.67 5.13 0.36 0.70 
120 79.43 4.52 80.13 4.81 80.50 4.87 0.39 0.68 
135         
150         
165         
180         
*-Significant  
TABLE-12 
INTRA OPERATIVE SYSTOLIC BLOOD PRESSURE IN mmHg 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 125.37 8.73 126.90 7.17 127.17 9.31 0.40 0.67 
30 124.33 8.01 127.10 9.71 129.37 8.39 2.87 0.06 
45 131.50 8.64 127.10 9.71 129.37 6.39 0.01 1.00 
60 122.63 7.12 125.90 6.52 125.37 7.56 1.06 0.35 
75 125.43 7.76 125.17 7.79 123.27 6.60 0.76 0.47 
90 123.43 8.59 125.30 9.32 123.67 6.14 0.47 0.62 
105 124.73 7.62 124.20 7.23 125.87 5.99 0.45 0.64 
120 126.47 5.54 124.57 5.46 124.60 8.22 0.83 0.44 
135         
150         
165         
180         
*-Significant 
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TABLE-13 
INTRA OPERATIVE DIASTOLIC BLOOD PRESSURE IN mmHg 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 79.83 6.63 80.73 7.33 82.17 6.23 0.91 0.41 
30 79.23 7.58 80.93 8.15 81.33 7.68 0.61 0.55 
45 77.50 5.95 80.37 7.62 80.53 7.73 1.71 0.19 
60 78.30 7.31 80.27 6.51 79.17 6.81 0.62 0.54 
75 78.73 8.42 80.87 7.99 79.73 6.75 0.57 0.57 
90 81.13 6.66 80.57 8.05 79.60 6.30 0.36 0.70 
105 78.90 6.37 79.17 6.01 80.10 7.98 0.26 0.88 
120 79.13 6.42 80.97 6.57 76.60 7.83 2.97 0.06 
135         
150         
165         
180         
*-Significant 
TABLE-14 
INTRA OPERATIVE MEAN  BLOOD PRESSURE IN mmHg 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 93.17 7.90 95.00 6.78 93.70 6.41 0.54 0.59 
30 93.00 7.15 93.90 8.64 95.90 6.04 1.22 0.30 
45 93.17 5.58 95.73 7.51 95.07 7.30 1.13 0.33 
60 91.23 6.11 93.90 5.75 92.43 7.97 1.20 0.31 
75 91.97 7.37 95.50 7.51 91.77 7.11 2.46 0.09 
90 94.73 7.33 93.07 7.92 94.07 6.09 0.41 0.66 
105 92.90 6.04 92.50 6.39 94.60 6.26 0.96 0.39 
120 94.63 5.10 92.50 6.58 91.90 7.85 1.42 0.25 
135         
150         
165         
180         
*-Significant 
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INTRAOPERATIVE TEMPERATURES 
TABLE-15.  
INTRA OPERATIVE SURFACE TEMPERATURE 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 36.60 0.14 36.58 0.13 36.59 0.11 0.22 0.81 
30 36.51 0.10 36.49 0.10 36.48 0.10 0.10 0.91 
45 36.22 0.30 36.16 0.33 36.10 0.36 0.003 1.00 
60 36.08 0.26 36.15 0.23 36.14 0.23 0.09 0.92 
75 36.05 0.22 36.06 0.20 36.02 0.34 0.01 1.00 
90 36.02 0.24 36.06 0.16 36.11 0.17 0.08 0.92 
105 35.95 0.31 35.94 0.19 35.93 0.23 0.01 1.00 
120 35.89 0.22 35.92 0.19 35.92 0.18 0.002 1.00 
135         
150         
165         
180         
*-Significant 
TABLE-16. 
INTRA OPERATIVE OT TEMP 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 22.47 0.28 22.50 0.26 22.56 0.27 0.96 0.39 
30 22.49 0.33 22.48 0.24 22.52 0.23 0.28 0.76 
45 22.39 0.38 22.47 0.28 22.52 0.24 1.34 0.27 
60 22.37 0.40 22.50 0.27 22.52 0.24 2.11 0.13 
75 22.38 0.37 22.47 0.36 22.57 0.31 2.32 0.11 
90 22.48 0.28 22.60 0.44 22.53 0.27 1.17 0.35 
105 22.49 0.33 22.48 0.34 22.56 0.27 1.30 0.28 
120 22.28 0.46 22.49 0.34 22.56 0.27 1.46 0.24 
135         
150         
165         
180         
*-Significant 
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TABLE-17.          INTRA OPERATIVE CORE TEMPERATURE 
  
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 36.64 0.12 36.64 0.12 36.64 0.12 0.01 1.00 
30 36.64 0.10 36.64 0.10 36.64 0.10 0.01 1.00 
45 36.59 0.19 36.59 0.19 36.59 0.19 0.01 1.00 
60 36.64 0.10 36.64 0.10 36.64 0.10 0.01 1.00 
75 36.62 0.09 36.62 0.09 36.62 0.09 0.01 1.00 
90 36.62 0.09 36.62 0.09 36.62 0.09 0.01 1.00 
105 36.62 0.09 36.62 0.09 36.62 0.09 0.01 1.00 
120 36.62 0.15 36.59 0.19 36.59 0.19 0.18 0.84 
135         
150         
165         
180         
*-Significant 
The   P- values   for   intraoperative  vitals  Heart rate , SBP, DBP, MAP, 
Core temperature, surface temperature ,and OT temperatures  were 
insignificant  compared between three groups. They were shown in 
above tables. 
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After extubation post operative, Heart rate, SBP, DBP, MAP and SPO2.  
Core temperature with nasopharyngeal probes, operation room 
temperature, and surface temperature with skin probes were monitored 
at 15, and 30 minutes. The P- values of post operative vitals and 
temperatures were insignificant, comparable between three groups. They 
were shown in following tables. 
POST OPERATIVE VITALS  
TABLE-18. 
POST OPERATIVE HEART RATE/MIN 
TIME GROUP-I GROUP-II GROUP-III F-value P-
Value 
Mean Sd Mean Sd Mean Sd 
15 87.50 6.26 87.17 6.16 87.50 6.08 0.03 0.97 
30 87.90 4.68 87.77 5.62 87.07 6.16 0.20 0.82 
*-Significant 
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TABLE-19. 
POST OPERATIVE SYSTOLIC BLOOD PRESSURE  mmHg 
 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 126.53 3.44 126.83 5.94 126.20 3.21 0.16 0.86 
30 128.37 5.06 127.70 4.07 127.50 4.54 0.30 0.75 
*-Significant  
 
TABLE-20.   POST OPERATIVE DIASTOLIC BLOOD  PRESSURE  in mmHg 
 
TIME GROUP-I GROUP-II GROUP-III F-value P-
Value 
Mean Sd Mean Sd Mean Sd 
15 76.00 4.14 76.53 4.37 78.40 4.04 2.72 0.07 
30 78.53 3.58 77.23 4.11 78.27 4.32 0.88 0.42 
*-Significant  
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TABLE-21. 
 POST  OPERATIVE MEAN ARTERIAL PRESSURE  in mmHg 
TIME GROUP-I GROUP-II GROUP-III F-value P-
Value 
Mean Sd Mean Sd Mean Sd 
15 92.67 3.62 93.10 4.33 92.67 3.81 0.12 0.89 
30 94.37 3.74 93.60 3.87 94.17 3.96 0.32 0.73 
*-Significant  
TABLE-22   POST OPERATIVE SPO2% 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 99.00 0 99.00 0 99.00 0   
30 99.00 0 99.00 0 99.00 0   
*-Significant 
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TABLE-25. POST OPERATIVE  ROOM TEMP 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 22.39 0.38 22.37 0.40 22.38 0.37 0.04 0.96 
30 22.48 0.28 22.44 0.35 22.49 0.33 0.20 0.82 
*-Significant  
 
TABLE-26.   
 
POST  OPERATIVE CORE TEMPERATURE 
TIME GROUP-I GROUP-II GROUP-III F-
value 
P-
Value 
Mean Sd Mean Sd Mean Sd 
15 36.64 0.10 36.61 0.15 36.64 0.10 0.65 0.53 
30 36.64 0.10 36.64 0.10 36.59 0.19 1.21 0.30 
*-Significant 
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TABLE-27.POSTOPERATIVE SURFACE TEMPERATURE 
TIME GROUP-I GROUP-II GROUP-III F-value P-Value 
Mean Sd Mean Sd Mean Sd 
15 36.62 0.09 36.62 0.15 36.68 0.39 0.62 0.54 
30 36.62 0.09 36.58 0.13 36.62 0.09 1.52 0.23 
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TABLE-28. 
Variation in core Temperature score (Mean±sd) 30 Minutes 
 Group-I Group-II Group-III p-value Significant 
Pre-operative 36.64±0.12 36.67±0.12 36.67±0.11 0.48 NS 
Post-operative(30min) 36.64±0.10 36.64±0.10 36.59±0.11 0.30 NS 
Operative Difference 0.00±0.02 0.03±0.02 0.08±0.00 0.53 NS 
** ANOVA Test 
 
Iintraoperative   and   post operative temperature changes  of  P – value 
were not significant for three groups. 
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POST OPERATIVE SHIVERING SCORE 
 
TABLE. 29. 
 
TIME 0(%) 1(%) 2(%) 3(%) Chi-Square p-value Significan
t 
15 Group-I 25 
(83.33) 
2 (6.67) 1 
(3.33) 
2 
(6.67) 
 
 
 
31.48 
 
 
 
0.000 
 
 
 
Significant 
Group-II 22 
(73.33) 
2 
(6.67) 
3 
(10.00) 
3 
(10.00) 
Group-III 8 
(26.67) 
1 
(3.33) 
3 
(10.00) 
18 
(60.00) 
30 Group-I 25 
(83.33) 
2 (6.67) 1 
(3.33) 
2 
(6.67) 
 
 
 
31.48 
 
 
 
0.000 
 
 
 
Significant 
Group-II 22 
(73.33) 
2 
(6.67) 
3 
(10.00) 
3 
(10.00) 
Group-III 8 
(26.67) 
1 
(3.33) 
3 
(10.00) 
18 
(60.00) 
 
Post operative shivering graded after extubation at 15, and 30 minutes 
interval. No shivering occurs in Pethidine group 83.3% (n=25), 
Granisetron 73% (n=22), placebo group27% (n=8) P-value statistically 
not significant between Granisetron and Pethidine groups but significant 
(P<0.05) in placebo group. Shivering  occurs at grade 3 in  Pethidine 
group 7% (n=2), Granisetron10%(n=3), placebo group60%(n=18) P-
value statistically not significant between Granisetron and Pethidine 
groups but significant in placebo group(P<0.05). 
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                                          DISCUSSION 
              The incidence of shivering in general  anaesthesia  is  about  
40%  to 60 % (23) which   depends upon the age, sex, drugs used  and the 
duration of the surgery. The shivering can increase metabolic rate 600% 
above the basal value Postanaesthetic shivering is  not only causing 
discomfort to the patients   also  increasing  postoperative pain,   also 
causes several physiological changes such as increased     increased  the 
tissue  oxygen consumption and carbondioxide production and Lactic 
acidosis, mixed  venous oxygen desaturation, and hypoxemia.  which  
increase in minute ventilation , cardiac output  and  metabolic  oxygen  
demand which results in increased stress on the  patients with limited 
cardiopulmonary reserve and old age. Shivering is one of the low 
morbidity clinical outcomes among 33 causes  was ranked  as the sixth 
most important problem. During general  anaesthesia onset of core 
hypothermia contributed by three factors which includes central 
thermoregulatory impairment, redistribution of heat from central to 
periphery, heat loss to the environment. The interthreshold range 
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increased for shivering and vasoconstriction .The cool ambient 
temperature environment in operation theater and cold intravenous fluids 
further decrease the temperature and cause shivering. In our study use of 
Granisetron 40µgm, and Pethidine25mg intravenously 5 minutes before 
induction of  anaesthesia in patients undergoing general anaesthesia. 
Granisetron is 5HT  receptor antagonist which used as an antiemetic 
clinically. Serotoninergic pathways play a significant role in the 
regulation of postoperative  shivering. In our study no shivering  occurs  
in  Pethidine group 83.3%(n=25), Granisetron 73%(n=22), placebo 
group 27% (n=8) P-value statistically not significant between 
Granisetron and Pethidine groups but significant(P<0.05) in placebo 
group. Shivering   occurs at grade 3 in  Pethidine group 7%(n=2), 
Granisetron 10% (n=3), placebo group 60% (n=18) P-value statistically 
not significant between Granisetron and Pethidine groups but significant 
in placebo group(P<0.05). Similar    results  were  derived by Asif Iqbal 
et al (1). In  Asif Iqbal  and his colleagues study 2 patients in Pethidine 
group , 6 patients in Granisetron group had shivering they found  that  
both drugs are equally effective for the  prevention  of  postoperative 
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shivering. Powell and Buggy studied Ondansetron, a 5-HT3 antagonist 
and   found that an intravenous dose of 8 mg a just prior to the induction 
of general anesthesia significantly reduced the incidence of 
postoperative  shivering. This effect is probably due to a central 
inhibitory mechanism, given  that there was no measurable effect on 
heat redistribution. These observations suggest that the serotoninergic 
pathways play a significant role in the regulation of postoperative  
shivering. Operation  theater temperature  no significant change in pre 
operative and postoperative  in all three groups. Compare to placebo 
group shivering was significantly reduced in both Granisetron and 
Pethidine group. Beween study drug Granisetron and control group 
Pethidine equally effective. 
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                                               SUMMARY  
 
From   this Prospective Randomized  Double Blind Study   we compared 
the Prophylactic  Granisetron 40µgm per Kg body weight versus 
Pethidine 25mg, for the Prevention  of  Postoperative Shivering in 
patients undergoing Elective Thyroid  Surgeries. During   study and 
statistical analysis the following points   were noted. The demographic 
profile like age, sex, weight, and height were compatible between three 
groups and statistically not significant. From our study we found that   
Granisetron and Pethidine were equally effective in preventing 
postoperative shivering when compared to placebo group  
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                                     CONCLUSION 
 
From this study the prophylactic use of both Granisetron and Pethidine 
were equally effective for the prevention of postoperative shivering.                 
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 VASANTHA 42 F 60 152 88 122 82 95 99 36.7 22.6 36.5
2 KANAGAMMA 58 F 58 156 78 138 88 96 99 36.8 22.2 36.6
3 MANGMMAL 52 F 62 154 80 130 80 96 99 36.7 22.1 36.7
4 SEVANTHI 58 F 64 148 82 128 76 80 99 36.8 22.6 36.5
5 SANGEETHA 42 F 56 154 86 122 74 90 99 36.6 22.4 36.4
6 SUSHEELA 34 F 52 156 88 134 82 99 99 36.7 22.3 36.8
7 SUMATHI 38 F 58 158 90 110 70 83 99 36.8 22.5 36.6
8 SEETHA 39 F 49 157 84 126 70 88 99 36.5 22.4 36.5
9 SIVAGAMI 43 F 59 156 78 138 70 92 99 36.9 22.3 36.6
10 MANJULA 54 F 52 162 72 120 86 99 99 36.5 22.5 36.6
11 MALAR 43 F 58 152 76 120 72 88 99 36.7 22.2 36.5
12 MEENATCHI 48 F 48 154 78 114 72 86 99 36.7 22.4 36.8
13 CHINNAPONNU 56 F 51 156 68 118 78 99 99 36.8 22.5 36.6
14 KALAIVANI 32 F 61 158 76 122 80 94 99 36.7 22.2 36.7
15 TAMILSELVI 26 F 56 164 74 126 80 95 99 36.7 22.4 36.5
16 RADHAA 38 F 47 162 82 132 62 95 99 36.5 22.1 36.5
17 SULOCHANA 42 F 52 158 86 128 78 94 99 36.6 22.5 36.8
18 VELATH 59 F 58 156 77 114 74 86 99 36.6 22.4 36.7
19 SUMATHI 44 F 54 152 72 118 69 85 99 36.8 22.3 36.6
20 MADHU 46 F 56 154 78 115 71 85 99 36.7 22.2 36.6
21 MALARVIZHI 36 F 64 150 82 124 85 95 99 36.5 22.6 36.8
22 UMA 32 F 66 158 92 123 84 95 99 36.6 22.5 36.7
23 YESOTHA 46 F 62 152 84 136 80 95 99 36.7 22.3 36.8
24 SARANYA 32 F 67 154 72 123 81 100 99 36.7 22.4 36.5
25 VASANTHA 55 F 62 152 76 123 88 99 99 36.8 22.6 36.7
26 PAPA 58 F 56 156 78 115 82 98 99 36.5 22.3 36.4
27 ALAMELU 54 F 54 154 82 120 73 86 99 36.7 22.4 36.6
28 RANI 56 F 52 152 89 127 70 90 99 36.6 22.4 36.5
29 SOLAI 49 F 58 158 86 132 75 95 99 36.5 22.2 36.7
30 KALA 52 F 48 152 76 122 80 90 99 36.7 22.5 36.4
S. No NAME AGE SEX WT kg HT cms HR/MIN SBPmmHg OT TEMP SURFACE TEMP
GROUP-3
DBPmmHg MAPmmHg SPO2%  CORE TEMP
15 30 45 60 75 90 105 120 135 150 165 180 15 30 45 60 75 90 105 120 135 150 165 180 15 30 45 60 75 90 105 120 135 150 165 180
83 74 68 94 76 74 72 74 118 124 122 122 128 118 116 120 78 74 70 88 70 76 70 74
75 77 86 82 81 82 75 72 125 116 114 120 116 109 130 117 91 88 78 76 71 69 81 73
79 76 85 88 95 92 72 71 137 130 142 138 124 118 128 118 86 86 91 74 70 72 81 76
79 80 82 86 78 74 86 78 130 143 143 129 130 124 132 135 86 85 84 70 81 82 76 90
74 78 84 86 88 90 87 86 143 136 136 125 120 132 136 128 84 84 92 81 70 72 92 70
78 84 82 87 83 86 82 84 134 118 128 1130 136 130 118 128 88 73 73 86 92 85 69 77
84 78 86 82 84 79 84 78 132 132 156 132 112 134 134 118 79 82 98 82 76 88 88 74
86 82 84 75 70 78 86 82 134 136 130 145 132 132 112 132 88 92 86 90 79 82 76 76
78 84 78 74 74 76 74 84 116 135 149 121 116 135 126 115 88 90 82 80 88 90 96 81
82 78 84 75 72 74 72 76 149 136 132 122 132 132 130 129 96 92 72 66 72 75 85 76
84 76 78 76 76 72 76 82 84 117 118 120 130 120 116 123 121 118 72 78 74 85 76 77 88 86 69
82 78 86 78 89 86 82 84 122 132 124 128 124 121 119 115 88 88 84 81 84 74 76 70
84 86 78 86 87 82 78 86 137 133 142 119 123 120 135 134 79 85 96 76 81 82 90 88
85 82 84 82 84 86 84 78 122 130 130 118 122 122 132 120 72 80 72 78 76 74 70 74
78 84 86 84 82 85 82 84 138 137 133 132 122 134 122 124 88 96 85 88 88 88 81 84
84 78 81 78 72 78 72 76 128 122 134 121 122 124 132 134 81 88 88 74 88 84 86 88
78 86 76 83 78 76 78 82 122 132 124 126 119 124 130 130 86 72 84 80 76 84 72 85
89 83 84 82 84 82 86 84 120 130 134 120 122 124 122 130 74 80 82 86 72 82 81 68
82 75 76 78 72 74 79 82 125 128 130 114 116 118 125 100 84 75 81 87 80 78 84 60
78 76 86 84 78 72 73 78 118 130 132 118 126 126 118 128 73 80 76 72 83 80 74 77
86 78 86 82 84 78 76 72 134 132 128 124 121 122 130 130 82 72 81 85 81 88 81 68
84 82 84 86 90 85 78 82 134 132 130 111 104 122 128 118 85 72 81 68 80 88 88 72
76 78 86 82 86 82 84 86 120 127 120 126 122 117 124 130 73 89 73 80 88 73 85 64
84 82 86 83 84 76 78 72 105 120 134 130 130 127 130 122 85 68 68 68 86 89 77 80
78 72 76 82 86 82 76 82 132 122 128 117 130 120 126 116 85 87 77 73 85 73 85 88
72 76 74 84 78 83 87 86 88 120 133 126 122 125 120 120 130 132 73 86 80 88 81 70 86 64 79
76 78 76 86 83 82 85 88 130 132 130 121 122 123 120 121 78 68 68 86 66 73 68 78
73 78 82 81 75 76 82 84 120 126 131 136 124 121 126 123 85 74 80 76 85 78 70 73
88 74 84 88 83 82 86 83 122 126 129 128 130 121 128 132 78 81 84 75 81 78 83 84
78 72 78 80 86 89 78 79 131 133 134 136 128 124 124 140 80 75 76 76 86 84 64 80
INTRA 0PERATIVE HEART RATE/MIN INTRA OPERATIVE SYSTOLIC  BLOOD PRESSURE IN mmHg
INTRAOPERATIVE DIASTOLIC BLOOD PRESSURE IN 
mmHg
15 30 45 60 75 90 105 120 135 150 165 180 15 30 45 60 75 90 105 120 135 150 165 180 15 30 45 60 75 90 105 120 135 150 165 180
91 90 86 99 90 91 85 81 36.5 36.3 36.4 36.3 34.6 36.4 36.3 36.2 22.2 22.4 22.4 23.2 22.5 22.6 22.7 22.8
91 93 90 86 86 80 85 79 36.6 36.5 36.4 36.2 35.8 36.1 36.2 36.1 22.8 22.8 22.5 22.4 22.6 22.4 22.4 22.8
103 95 108 81 81 87 95 76 36.7 36.5 36.4 36.2 36.6 36.8 36.7 36.7 22.3 23.2 22.4 23.2 22.8 22.5 23 22.4
95 112 112 86 86 96 96 105 36.5 36.7 36.5 36.8 36.1 36.2 36.8 36.8 22.5 22.7 22.6 22.5 22.3 22.7 22.5 22.5
112 103 92 91 91 96 103 90 36.4 36.5 36.8 36.5 36.7 36.5 36.6 36.4 22.4 22.6 22.7 22.4 22.2 22.6 22.4 22.6
93 85 86 95 95 94 92 96 36.8 36.5 36.6 36.6 36.4 36.8 36.7 36.2 22.7 22.4 22.6 22.6 23.2 22.8 22 22.7
93 100 88 100 92 93 93 95 36.6 36.4 36.7 36.5 36.6 36.2 36.6 36.7 22.8 22.3 22.2 22.3 22.7 22.5 22.6 22.3
93 103 95 114 103 100 90 90 36.5 36.6 36.8 36.8 36.1 36.4 36.8 36.5 22.9 22.5 22.4 22.5 22.3 22.2 22.7 22.9
93 105 99 103 93 105 107 92 36.6 36.4 36.5 36.2 36.6 36.4 36.2 36.8 22.5 22.2 22.5 22.6 22.7 22.6 22.7 22.4
96 103 96 77 96 95 94 86 36.6 36.4 36.8 36.6 36.2 36.8 36.1 36.7 22.4 22.7 22.8 22.3 22.2 22.3 22.3 22.6
83 98 89 100 96 86 102 104 85 36.5 36.4 36.4 36.1 36.2 36.2 35.8 36.8 36.2 22.3 22.4 22.6 22.5 22.6 22.4 22.6 22.4 22.8
99 96 101 95 101 96 88 90 36.8 36.4 36.4 36.6 36.5 36.7 36.2 36.6 22.6 22.2 23.2 22.4 22.8 22.5 22.5 22.3
89 98 110 88 89 96 92 103 36.6 36.5 36.6 36.2 36.1 36.2 36.1 36.7 22.7 22.5 22.3 22.5 22.4 22.6 22.3 22.8
88 96 90 91 89 90 90 93 36.7 36.5 36.8 36.2 36.4 36.5 36.8 36.2 22.8 22.3 22.6 22.2 22.3 22.7 22.4 23.2
90 89 98 96 99 103 94 101 36.5 36.4 36.8 36.8 36.4 36.2 36.8 36.6 22.9 22.4 22.8 22.3 22.4 22.6 22.8 23.4
95 95 103 96 99 101 96 95 36.6 36.4 36.4 36.7 35.8 36.6 36.4 36.4 22.3 22.9 22.7 22.6 22.8 22.2 22.7 22.5
98 91 101 88 88 101 90 96 36.5 36.6 36.4 36.2 36.8 36.1 36.7 36.8 22.4 22.8 22.5 22.4 23.2 22.4 22.6 22.6
93 96 99 99 88 96 94 88 36.7 36.3 36.5 36.4 36.2 36.5 36.6 36.2 22.5 22.7 22.3 22.5 23.4 22.5 22.3 22.5
95 88 95 91 92 98 95 71 36.7 36.5 36.4 36.6 36.4 36.6 36.2 36.4 22.3 22.6 22.4 22.8 22.9 22.4 22.5 22.6
98 96 96 78 70 88 98 90 36.4 36.5 36.4 36.2 36.8 36.4 35.9 36.8 23.2 22.3 22.5 22.6 22.5 23.2 22.4 22.2
99 91 95 95 95 99 95 88 36.5 36.4 36.4 36.7 36.5 36.5 36.5 36.8 22.5 22.4 22.3 22.2 22.3 23.4 23.2 22.6
103 91 95 79 88 99 103 88 36.5 36.6 36.4 36.2 36.2 36.5 36.4 36.6 22.2 22.3 22.5 22.4 22.5 22.4 22.9 22.2
88 100 80 95 99 87 98 95 36.6 36.3 36.5 36.4 36.2 36.8 36.5 36.2 22.4 22.6 22.7 22.6 22.2 22.3 22.7 22.4
78 88 85 90 95 100 100 94 36.5 36.5 36.4 36.2 36.8 36.5 36.2 36.1 22.2 22.8 22.5 22.8 22.5 22.2 22.8 22.6
96 99 96 87 94 86 96 93 36.8 36.5 36.4 36.6 36.3 36.4 36.8 36.8 23.2 22.6 22.6 22.6 22.6 22.3 22.6 22.4
99 100 95 99 91 88 88 95 93 36.6 36.7 36.5 36.8 36.5 36.2 36.6 36.7 36.4 22.6 22.4 22.5 22.7 22.6 22.2 22.3 22.5 22.4
88 96 90 94 77 90 92 90 36.7 36.5 36.6 36.2 36.7 36.2 36.4 36.8 22.5 22.2 22.4 22.4 22.5 22.4 22.5 22.3
89 90 90 96 95 90 96 97 36.5 36.5 36.5 36.2 36.4 36.7 36.6 36.2 22.7 22.5 22.3 22.2 22.3 22.6 22.4 22.7
93 90 96 88 95 90 109 96 36.6 36.4 36.7 36.5 36.8 36.2 36.8 36.6 22.5 22.6 22.5 22.4 22.5 22.8 23.2 22.3
90 100 96 96 100 101 82 100 36.7 36.6 35.8 35.9 36.1 36.4 35.8 36.8 22.5 22.4 22.2 22.5 22.3 22.6 22.3 22.4
INTRAOPERATIVE MEAN BLOOD PRESSURE IN mmHg INTRA OPERATIVE SURFACE TEMPERATURE INTRA OPERATIVE OT TEPERATURE
15 30 45 60 75 90 105 120 135 150 165 180 15 30 15 30 15 30 15 30 15 30 15 30 15 30
36.6 36.6 36.7 36.5 36.6 36.6 36.6 36.7 86 88 132 126 80 74 97 91 99 99 22.4 22.8 36.6 36.7
36.5 36.5 36.6 36.6 36.6 36.5 36.6 36.6 88 90 134 128 72 76 99 90 99 99 22.8 22.6 36.5 36.6
36.7 36.7 36.5 36.7 36.7 36.7 36.7 36.5 96 82 136 134 82 80 100 98 99 99 22.2 23.2 36.7 36.5
36.8 36.7 36.8 36.8 36.5 36.7 36.5 36.8 84 78 138 130 84 78 102 96 99 99 22.6 22.6 36.7 36.8
36.8 36.8 36.7 36.7 36.6 36.6 36.6 36.7 82 86 132 126 80 84 97 98 99 99 22.8 22.4 36.8 36.7
36.6 36.5 36.6 36.5 36.6 36.5 36.6 36.6 92 90 138 132 84 70 102 87 99 99 21.4 22.6 36.5 36.6
36.6 36.6 36.5 36.6 36.6 36.7 36.6 36.5 86 84 136 124 80 72 98 99 99 99 22.5 22.5 36.6 36.5
36.5 36.5 36.6 36.5 36.5 36.6 36.5 36.6 78 83 132 122 80 72 94 88 99 99 21.9 22.3 36.5 36.6
36.7 36.6 36.5 36.6 36.6 36.7 36.6 36.5 82 79 128 132 78 82 94 96 99 99 21.7 22.8 36.6 36.5
36.9 36.7 367 36.6 36.6 36.8 36.6 367 86 84 130 126 82 72 98 90 99 99 22.8 22.3 36.7 367
36.5 36.6 36.6 36.7 36.5 36.6 36.5 36.6 36.6 88 87 126 128 70 82 98 97 99 99 22 22.4 36.6 36.6
36.6 36.7 36.7 36.7 36.8 36.7 36.8 36.7 84 92 136 126 78 76 94 92 99 99 22.8 22.3 36.7 36.7
36.6 36.6 36.6 36.6 36.6 36.5 36.6 36.6 78 86 134 118 80 80 97 92 99 99 22.6 22.2 36.6 36.6
36.7 36.7 36.7 36.7 36.7 36.6 36.7 36.7 90 88 122 124 72 78 88 91 99 99 22.4 21.2 36.7 36.7
36.5 36.8 36.8 36.8 36.5 36.7 36.5 36.8 95 84 128 119 75 80 91 93 99 99 22.4 22.9 36.8 36.8
36.7 36.6 36.7 36.5 36.6 36.6 36.6 36.7 97 78 138 134 80 70 99 86 99 99 21.8 22.5 36.6 36.7
36.7 36.5 36.6 36.6 36.5 36.6 36.5 36.6 78 90 132 124 70 78 87 92 99 99 22.7 22.6 36.5 36.6
36.6 36.7 36.5 36.7 36.7 36.7 36.7 36.5 84 95 128 130 76 84 93 99 99 99 22.2 22.7 36.7 36.5
36.4 36.7 36.8 36.8 36.7 36.5 36.7 36.8 86 97 126 132 80 78 95 96 99 99 22.3 22.5 36.7 36.8
36.6 36.8 36.7 36.7 36.6 36.6 36.6 36.7 78 78 130 134 80 80 96 96 99 99 22 22.3 36.8 36.7
36.7 36.5 36.6 36.5 36.5 36.6 36.5 36.6 79 84 132 128 76 78 96 94 99 99 22.4 22.7 36.5 36.6
36.8 36.6 36.5 36.6 36.7 36.6 36.7 36.5 92 86 136 126 83 80 99 95 99 99 22.7 22.6 36.6 36.5
36.5 36.5 36.6 36.5 36.6 36.5 36.6 36.6 98 78 133 128 78 86 97 101 99 99 22.6 22.8 36.5 36.6
36.6 36.6 36.5 36.6 36.7 36.6 36.7 36.5 94 79 135 122 75 82 95 96 99 99 22.5 22.5 36.6 36.5
36.8 36.7 367 36.6 36.8 36.6 36.8 367 92 92 128 126 80 80 96 95 99 99 22.8 22.3 36.7 367
36.7 36.6 36.6 36.7 36.6 36.5 36.6 36.6 36.7 86 98 136 130 82 80 99 96 99 99 22.5 22.5 36.6 36.6
36.6 36.7 36.7 36.7 36.7 36.8 36.7 36.7 90 94 134 132 75 82 94 98 99 99 22.2 22.3 36.7 36.7
36.5 36.6 36.6 36.6 36.5 36.6 36.5 36.6 96 92 128 132 80 80 99 97 99 99 22.5 22.5 36.6 36.6
36.7 36.7 36.7 36.7 36.6 36.7 36.6 36.7 90 96 128 120 85 72 99 88 99 99 22.8 22.3 36.7 36.7
36.6 36.8 36.8 36.8 36.7 36.5 36.7 36.8 90 94 134 132 75 82 94 98 99 99 22 22.4 36.8 36.8
POST 
OPERATIVE 
HEART 
RATE/MIN
POST 
OPERATIVE SBP   
IN  mmHg  
POST OPERTIVE 
DBP IN mmHg
POST 
OPERATIVE MAP 
IN mmHg
INTRA OPERATIVE CORE TEMPERATURE
POST 
OPERATIVE 
CORE 
TEMPERATURE
POST 
OPERATIVE 
SPO2%
POST OP ROOM 
TEMP
15 30 5 10 15 20 25 30 NAUSEA VOMITING TACHYCARDIA HYPOTENSION DESATURATION
36.8 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.5 3 3 3 3 3 3 NO NO NO NO NO
36.6 36.7 0 ; 0 0 0 0 NO NO NO NO NO
36.5 36.7 3 3 3 3 3 3 NO NO NO NO NO
36.6 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.5 36.5 1 1 1 1 1 1 NO NO NO NO NO
36.7 36.7 0 0 0 0 0 0 NO NO NO NO NO
36.6 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.7 2 2 2 2 2 2 NO NO NO NO NO
36.6 36.8 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.8 36.7 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.5 3 3 3 3 3 3 NO NO NO NO NO
36.6 36.6 0 0 0 0 0 0 NO NO NO NO NO
36.5 36.7 3 3 3 3 3 3 NO NO NO NO NO
36.8 36.6 0 0 0 0 0 0 NO NO NO NO NO
36.7 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.6 36.7 3 3 3 3 3 3 NO NO NO NO NO
36.5 36.5 0 0 0 0 0 0 NO NO NO NO NO
36.6 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.5 36.6 2 2 2 2 2 2 NO NO NO NO NO
367 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.6 36.5 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.6 0 0 0 0 0 0 NO NO NO NO NO
36.6 36.6 3 3 3 3 3 3 NO NO NO NO NO
36.7 36.5 0 0 0 0 0 0 NO NO NO NO NO
36.8 36.8 3 3 3 3 3 3 NO NO NO NO NO
36.6 0 0 0 0 0 0 NO NO NO NO NO
36.7 2 2 2 2 2 2 NO NO NO NO NO
36.5 3 3 3 3 3 3 NO NO NO NO NO
POSTOP 
SURFACE TEMP
POST OPERATIVE 
SHIVERING SCORE
COMLICATION
  
PATIENT CONSENT FORM 
 
STUDY TITLE: 
        A Prospective, Randomized Comparative study to Compare the 
Effectiveness of Prophylactic Granisetron versus Pethidine for the  Prevention 
of postoperative Shivering in Patients Undergoing Elective thyroid surgeries. 
STUDY  CENTER: 
Institute   of  Anaesthesiology  and Critical Care,  
Madras Medical college,  
Chennai- 600003. 
Participant name :                                     Age:         Sex:                                            
I.P.No: 
 
 I confirm that I have understood the purpose of procedure for the above  study. I 
have the opportunity to ask the question and all my questions and doubts have been 
answered to my satisfaction. I have been explained about the pitfall in the 
procedure. I have been explained about the safety, advantage and disadvantage of 
the technique.  
 
   I understand that my participation in the study is voluntary and that I am free to 
withdraw at anytime without giving any reason.  
 
     I understand that investigator, regulatory authorities and the ethical committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study. I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required under the law. 
I agree not to restrict the use of any data or results that arise from the study. 
 
Time :  
 
Date :                                                   Signature / Thumb impression of patient 
Place :                                                                                   Patient name:  
 
 
Signature of the investigator:                                     Name of the investigator: 
 
 
  
INFORMATION TO PARTICIPANTS 
Investigator: 
Name of the Participant: 
Title:         
A Prospective, Randomized Comparative Study to Compare the Effectiveness 
of Prophylactic Granisetron versus Pethidine for Prevention of Postoperative 
Shivering in Patients Undergoing Elective Thyrod Surgeries. 
 You are invited to take part in this research study. We have got approval from the 
Institutional Ethical Committee. You are asked to participate since you satisfy the 
eligibility criteria. We want to compare the effectiveness of prophylactic 
Granisetron versus Pethidine for prevention of postoperative shivering  in patients 
undergoing elective breast surgeries. 
Purpose of Research: 
For thyroid surgeries, prophylactic inj.Granisetron or inj,Pethidine iv given before 
induction then patient anaesthetized This study is done to compare effectiveness in 
prevention of postoperative shivering  in patients undergoing elective thyroid 
surgery with respect to,  
1. Base  line, Intra operative and post operative temperature ,BP,PR and SPO2 
2. Post operative shivering score for shivering 
The Study Design 
 All the patients in the study will be divided into three groups: 
Group1-    prophylactic inj,Granisetron 
  
Group2-    Prophylactic inj,Pethidine  
Group3.   Placebo saline  
  Drugs  Will be Given  IV  Before Induction  And All patients will be given 
general anaesthesia. 
Benefits: 
        Both Drugs Prevents  Postoperative  Shivering, Granisetron  also  Prevents  
Vomiting. 
Discomforts and Risks: 
 Nausea and Vomiting treated by  inj.metoclopramide 10mg. 
 Hypotension, Tachycardia may occur – emergency drugs will be readily available.                                       
   This intervention has been shown to be well tolerated by previous studies. But if 
you do not want to participate, you will be provided with an alternative setting of 
standard treatment. Your safety is our prime concern.  
Time: 
Place: 
Date:               
 Name of the Investigator :               Signature / Thumb impression o of the   patient 
                                          
Name of the Investigator   :                                     Name of the patient: 
                                                          
  
                                           PROFORMA 
Date: …………….                                                            Drug:                                               
Roll No.:  
Name: ……………………………………… 
Age:            Sex: ……..   Wt:        Kg,       Ht: …….Cms,               IP No:  
Diagnosis:                                            Surgical Procedure :  
 
Pre  operative Assessment :       General Anaethesia ,   ASA    I  /   II 
 
• H/O  Any Co-morbid illness :  
• H/O Documented Difficult Airway :  
• H/O previous surgeries  
 
  Examination:              
                                     CVS:  
                                           RS:  
                                          ABDOMEN:  
                                          CNS:  
 
Measures of Study Outcome: 
             Postoperative Shivering and Vitals for 30Minutes    
Shivering  Scale: 
Grade:  
               0- No shivering 
               1-  Piloerection ,no visible shivering 
2- Muscular activity in only one group  
3- Muscular activity in more than   one group  but not 
generalised   
                4- Shivering generalised involving whole body 
 
  
Time SBP 
mmHg 
DBP 
mmHg 
MAP 
mmHg 
SPO2 % PR Core 
Temp°C 
OT 
Temp°C 
Surface 
Temp°C 
Shivering 
score 
5 
 
         
10          
15          
20          
25          
30          
35          
40          
45          
50          
55          
60          
65          
70          
75          
80          
85          
90          
95          
100          
105          
110          
115          
120          
125          
130          
135          
140          
145          
150          
155          
160          
165          
170          
175          
180          
 
 Post operative period 
Time SBP 
mmHg 
DBP 
mmHg 
MAP 
mmHg 
SPO2 % PR Core 
Temp°C 
OT 
Temp°C 
Surface 
Temp°C 
Shivering 
score 
15          
30          
 
Complications: Nausea  / vomiting Tachycardia   / Bradycardia/Hypotension    
/Desaturation  
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